MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Simulations Plus Inc

Suletud

SektorTervishoid

16.46 -0.3

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.28

Max

16.74

Põhinäitajad

By Trading Economics

Sissetulek

-70M

-67M

Müük

-2.1M

20M

P/E

Sektori keskmine

48.528

35.739

Dividenditootlus

0.48

Kasumimarginaal

-330.585

Töötajad

243

EBITDA

-79M

-74M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+30.3% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

3.08%

Järgmine tulemuste avaldamine

22. okt 2025

Turustatistika

By TradingEconomics

Turukapital

-51M

300M

Eelmine avamishind

16.76

Eelmine sulgemishind

16.46

Uudiste sentiment

By Acuity

50%

50%

183 / 371 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2025, 16:58 UTC

Tulu

BMW Trims 2025 View, Citing Weaker Performance in China

7. okt 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. okt 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. okt 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. okt 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 20:44 UTC

Kuumad aktsiad

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. okt 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. okt 2025, 19:23 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. okt 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. okt 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. okt 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. okt 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. okt 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. okt 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. okt 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. okt 2025, 14:52 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

30.3% tõus

12 kuu keskmine prognoos

Keskmine 21.5 USD  30.3%

Kõrge 25 USD

Madal 16 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

183 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat